Similar articles

• HIV transmission may be prevented by intravaginal tenofovir ring.

  Parks L. Parks L. Future Med Chem. 2012 Dec;4(18):2239. Future Med Chem. 2012. PMID: 23359902 No abstract available.
• Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.

  Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Perri GD, Lanzafame M, Penco G. Calcagno A, et al. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):431-2. doi: 10.1097/QAI.0b013e3181b08f09. J Acquir Immune Defic Syndr. 2009. PMID: 19858926 No abstract available.
• Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.

  Burty C, Prazuck T, Truchetet F, Christian B, Penalba C, Salmon-Ceron D, Yazdanpanah Y, May T, Rabaud C. Burty C, et al. AIDS Patient Care STDS. 2010 Jan;24(1):1-3. doi: 10.1089/apc.2009.0263. AIDS Patient Care STDS. 2010. PMID: 20095911 No abstract available.
• Pre-exposure prophylaxis for HIV infection: what if it works?

  Paxton LA, Hope T, Jaffe HW. Paxton LA, et al. Lancet. 2007 Jul 7;370(9581):89-93. doi: 10.1016/S0140-6736(07)61053-8. Lancet. 2007. PMID: 17617276 Review. No abstract available.
• Tenofovir gel--the new HIV prevention 'banker'?

  Bateman C. Bateman C. S Afr Med J. 2007 Jul;97(7):496, 498. S Afr Med J. 2007. PMID: 17805450 Review. No abstract available.